PDF

Inari Medical, Inc. Class Action Lawsuit - NARI

47 days left to seek lead plaintiff status

Case Summary

Investors who suffered a loss and would like to learn more, click here to contact us.

The Inari Medical class action lawsuit seeks to represent purchasers of shares of Inari Medical, Inc. (NASDAQ: NARI) common stock between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”).  Captioned Michiana Area Electrical Workers’ Pension Fund v. Inari Medical, Inc., No. 24-cv-03686 (S.D.N.Y.), the Inari Medical class action lawsuit charges Inari Medical and certain of Inari Medical’s top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Inari Medical class action lawsuit, please provide your information in the form on this page.  You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.  Lead plaintiff motions for the Inari Medical class action lawsuit must be filed with the court no later than July 12, 2024.

CASE ALLEGATIONS: Inari Medical is a medical device company that specializes in developing, manufacturing, and commercializing catheter-based technologies.

The Inari Medical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that a significant portion of Inari Medical’s expenses were used to compensate medical professionals improperly for using Inari Medical’s products, in violation of the federal Anti-Kickback Statute and Civil False Claims Act.

The Inari Medical class action lawsuit further alleges that on February 28, 2024, Inari Medical disclosed that in December 2023 it had received a civil investigative demand from the U.S. Department of Justice, Civil Division in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals.  On this news, the price of Inari Medical common stock fell nearly 30% over four trading sessions, according to the Inari Medical class action lawsuit.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased shares of Inari Medical common stock during the Class Period to seek appointment as lead plaintiff in the Inari Medical class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Inari Medical class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Inari Medical class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Inari Medical class action lawsuit.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases.  The Firm was ranked #1 on the ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller topped the list.  And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.

Submit Your Information

Valid monetary value, for example, $1000.00

* indicates a required field

Main Menu